Hereditary Hypophosphatemic Rickets with Hypercalciuria Is Caused by Mutations in the Sodium-Phosphate Cotransporter Gene SLC34A3  by Lorenz-Depiereux, Bettina et al.
www.ajhg.org Lorenz-Depiereux et al.: HHRH Caused by SLC34A3 Mutations 193
Hereditary Hypophosphatemic Rickets with Hypercalciuria Is Caused
by Mutations in the Sodium-Phosphate Cotransporter Gene SLC34A3
Bettina Lorenz-Depiereux,1 Anna Benet-Pages,1 Gertrud Eckstein,1
Yardena Tenenbaum-Rakover,2 Janine Wagenstaller,1 Dov Tiosano,3 Ruth Gershoni-Baruch,3,4
Norbert Albers,5 Peter Lichtner,1 Dirk Schnabel,6 Ze’ev Hochberg,3,4 and Tim M. Strom1,7
1Institute of Human Genetics, GSF National Research Center for Environment and Health, Munich-Neuherberg, Germany; 2Pediatric
Endocrine Unit, Ha’ Emek Medical Center, Afula, Israel; 3Meyer Children’s Hospital and 4Technion–Israel Institute of Technology, Haifa,
Israel; 5Children’s Hospital, Osnabru¨ck, Germany; 6Department for Pediatric Endocrinology, Charite´, Berlin; and 7Institute of Human Genetics,
Klinikum rechts der Isar, Technical University, Munich
Hypophosphatemia due to isolated renal phosphate wasting results from a heterogeneous group of disorders.
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is an autosomal recessive form that is char-
acterized by reduced renal phosphate reabsorption, hypophosphatemia, and rickets. It can be distinguished from
other forms of hypophosphatemia by increased serum levels of 1,25-dihydroxyvitamin D resulting in hypercalciuria.
Using SNP array genotyping, we mapped the disease locus in two consanguineous families to the end of the long
arm of chromosome 9. The candidate region contained a sodium-phosphate cotransporter gene, SLC34A3, which
has been shown to be expressed in proximal tubulus cells. Sequencing of this gene revealed disease-associated
mutations in ﬁve families, including two frameshift and one splice-site mutation. Loss of function of the SLC34A3
protein presumably results in a primary renal tubular defect and is compatible with the HHRH phenotype. We
also show that the phosphaturic factor FGF23 (ﬁbroblast growth factor 23), which is increased in X-linked hy-
pophosphatemic rickets and carries activating mutations in autosomal dominant hypophosphatemic rickets, is at
normal or low-normal serum levels in the patients with HHRH, further supporting a primary renal defect. Iden-
tiﬁcation of the gene mutated in a further form of hypophosphatemia adds to the understanding of phosphate
homeostasis and may help to elucidate the interaction of the proteins involved in this pathway.
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Hypophosphatemia due to isolated renal phosphate
wasting can be caused by three well-deﬁned Mendelian
disorders: (1) X-linked hypophosphatemia (XLH [MIM
307800]), (2) autosomal dominant hypophosphatemic
rickets (ADHR [MIM 193100]), and (3) hereditary hy-
pophosphatemic rickets with hypercalciuria (HHRH
[MIM 241530]). The genes mutated in XLH and ADHR
have been identiﬁed as PHEX (HYP Consortium 1995)
and FGF23 (ADHR Consortium 2000), respectively,
whereas the gene mutated in HHRH has remained elu-
sive. Phosphate wasting is also a prominent feature of
tumor-induced osteomalacia (TIO), which is caused by
rare, mostly benign mesenchymal tumors that overex-
press ﬁbroblast growth factor 23 (FGF23) (Shimada et
al. 2001; White et al. 2001). Besides these well-deﬁned
conditions, there may be further Mendelian hypo-
phosphatemias, such as hypophosphatemic bone disease
and autosomal recessive hypophosphatemia without
hypercalciuria.
HHRH was ﬁrst described in a Bedouin tribe (Tieder
et al. 1985). Since that article, one other Bedouin kindred
and several sporadic cases have been described (Nishi-
yama et al. 1986; Chen et al. 1989; Tieder et al. 1992;
Schnabel et al. 1996; van den Heuvel et al. 2001). Like
other phosphate wasting disorders, HHRH is charac-
terized by reduced tubular reabsorption of phosphate
(TRP) and hypophosphatemia. However, in contrast to
the characteristics of XLH and ADHR, serum levels of
1,25-dihydroxyvitamin D (1,25(OH)2D) in HHRH are
appropriately elevated for low serum phosphorus levels
despite suppressed parathyroid function, and there is an
increase in urinary calcium excretion. It has been sug-
gested that the pivotal defect consists of renal phosphate
depletion, which stimulates renal 25-hydroxyvitamin D
1a-hydroxylase followed by an increase in 1,25(OH)2D
(Tieder et al. 1985), enhanced intestinal absorption of
calcium, and, subsequently, hypercalcemia. The accurate
diagnosis of HHRH has important therapeutic impli-
cations. Unlike for XLH and ADHR, phosphate sup-
plementation alone can cause a complete remission of
HHRH, whereas the addition of vitamin D can create
complications, such as hypercalcemia, nephrocalcinosis,
and renal damage.
HHRH is inherited in an autosomal recessive mode.
Obligate carriers of a single mutant allele have been
described to have borderline hypercalciuria but do not
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Table 1
Chemical Findings
CHARACTERISTIC
PATIENT
HETEROZYGOUS
INDIVIDUALSa
REFERENCE
VALUE23724 23727 27018 5669 5919
Age (years) 2 12 10 3.7 6 2–49 …
Calcium (mmol/liter) 2.45 2.42 2.35 2.26 2.54 2.2–2.3 2.15–2.64
Phosphate (mmol/liter)b .87 (1.23–1.94) .74 (1.03–1.70) .81 (1.10–1.87) .87 (1.22–2.13) .77c (1.16–1.91) 1.00–1.39 …
Alkaline phosphatase (U/liter)b 736 (60–500) 1,133 (80–224) 689 (60–500) 908 (182–446) 890 (110–500) 88–189 …
PTH (pg/ml)d 36 8.8 8.6 4.5 …e 18–68 12–65
25-hydroxyvitamin D (ng/ml) 8 25 29 14 24 16–31 12–48
1,25(OH)2D (pg/ml) 73 174 208 129 93 44–83 36–96
Urine calcium/creatine (mg/mg)b 1.24 (!.28) .55 (!.25) .66 (!.27) .89 (!.17) .26 (!.25) .23–.55 …
TRP (%) 91 78 82 74 87.6 83–88 83–95
TmP/GFRf 2.1 .9 2.0 2.0 … 2.9–4.1 2.5–4.2
a Heterozygous individuals are six parents and seven siblings.
b Given in parentheses are age- and sex-dependent reference values (Hochberg and Tiosano 2004).
c The patient had several phosphate levels within the low-normal range (4.1–4.9 mg/dl) during the ﬁrst months of evaluation.
d PTH p parathyroid hormone.
e At the time of diagnosis (before 1986), only PTH fragments could be measured. The value for C-terminal PTH (aa 35–84) was 0.4 ng/ml (normal 0.4–1.5).
Measurement of C-terminal PTH (aa 44–68) was 159 pg/ml (normal 100–300). Actual PTH level was !3 pg/ml.
f TmP/GFR p maximum tubular phosphate reabsorption per glomerular ﬁltration rate.
have hypophosphatemia or rickets. Here, we describe
the isolation of the gene mutated in HHRH by ge-
nomewide linkage analysis and mutation screening in a
candidate gene.
Material and Methods
Patients
A total of seven patients with HHRH and their relatives
from ﬁve families were included in this study. The patients
were admitted to the hospital with rickets at the age of 2 to
12 years. All showed low serum phosphate levels and reduced
or low-normal renal phosphate reabsorption. Alkaline phos-
phatase levels and urinary calcium excretion were clearly el-
evated. 1,25(OH)2D levels were elevated or highly normal,
whereas 25-hydroxyvitamin D was in the normal range. Table
1 shows representative values for ﬁve patients. We also in-
cluded 22 patients with hypophosphatemic rickets who were
referred to us for molecular genetic diagnostics and in whom
PHEX and FGF23 mutations have been excluded. We used
360 European individuals and 93 Israeli Arabic individuals as
controls.
Genetic Studies
Genomewide genotyping was performed using the Linkage
IV Panel from Illumina, which contains ∼5,600 SNP markers.
In addition, microsatellite markers were used in the candidate
region: D9S164, D9S1826, D9S158, D9S905, and D9S1838.
For the genomewide scan, frequencies of marker alleles were
derived from dbSNP as provided by Illumina. For microsat-
ellite analysis, the frequencies were based on the individuals
genotyped in this project. The map positions of these markers
were obtained by calculating the arithmetic mean of the sex-
speciﬁc distances taken from the Genetic Location Database
(Collins et al. 1996), by use of MAP-O-MAT version 1.1 (Lan-
der and Green 1987; Matise and Gitlin 1999). Data for linkage
analysis were prepared with a modiﬁed version of Alohomo-
ra (Rueschendorf and Nurnberg 2005). This tool uses Ped-
Check1.1 to detectMendelian or genotyping errors (O’Connell
and Weeks 1998) and uses Merlin to avoid unlikely genotypes
(Abecasis et al. 2002). Multipoint linkage analysis was per-
formed using Allegro (version 1.1d) (Gudbjartsson et al. 2000).
Mutation Analysis
SLC34A3 exons were ampliﬁed with intronic primers (table
A1) and were directly sequenced using a BigDye Cycle se-
quencing kit (Applied Biosystems). Genomic DNA (∼50 ng)
was subjected to PCR ampliﬁcation performed in a 25-ml vol-
ume containing 1# PCR buffer/1.5 mM MgCl2, dNTPs (200
mM of each dNTP), 1# Q-Solution, HotStar Taq DNA Poly-
merase (2.5 U/reaction [Qiagen]), and 0.25 mM of each for-
ward and reverse primer under the following cycle conditions:
initial step at 95C for 15 min; 10 cycles at 95C for 30 s, 70C
for 30 s, and 72C minus 1C/cycle for 30 s; 25 cycles at 95C
for 30 s, 58C for 30 s, and 72C for 30 s; and ﬁnal extension
at 72C for 10 min. Primers were designed with ExonPrimer.
Circulating FGF23 Levels
Plasma samples were isolated within 30 min after blood
withdrawal by centrifugation and were stored at70C before
biochemical analysis. FGF23 levels were measured using a
commercial C-terminal ELISA (Immutopics) and a full-length
FGF23 ELISA (Kainos Laboratories). The intra-assay coefﬁ-
cient of variation (CV) for the C-terminal assay is 5%, and
the interassay CV is 7.3%.
Results
Linkage Analysis
We identiﬁed three families of Arab origin and two
families of German origin with HHRH (ﬁg. 1). Seven
Figure 1 Mutation analysis of SLC34A3 in ﬁve families (left) and electropherograms of the affected individuals (right). The mutations
are indicated above the electropherograms. Families 1 and 2 presented homozygous mutations. Affected individuals from families 3 and 4 were
compound heterozygous. In the affected individual from family 5, we found only a heterozygous deletion. Affected individuals are indicated
by fully blackened symbols, and unaffected heterozygous individuals by half-blackened symbols.
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Figure 2 Multipoint linkage analysis of 15 cM of the telomeric end of the long arm of chromosome 9. The analyses were performed
using ALLEGRO ( ; ; ; ) and included affected and unaffected family members. Depicted are summary LODqp 0.001 f p 0.0 f p 0.0 f p 0.991 2 3
scores under the assumption of homogeneity. Analysis of SNP markers was performed in families (Fam) 1 and 2 (black line), and analyses of
microsatellite markers were performed in all families, once with (bottom gray line) and once without (top gray line) consanguinity in family
3. The SLC34A3 gene maps between D9S905 and D9S1838.
individuals in these families were classiﬁed as affected.
The parents of the Arab families were ﬁrst-degree cous-
ins. Diagnosis was based on rickets, reduced TRP, hy-
pophosphatemia, and hypercalciuria. Furthermore, mu-
tations in the coding regions of PHEX and FGF23 were
excluded by sequencing.
To identify the HHRH locus, we performed a ge-
nomewide linkage analysis by SNP genotyping, using the
Linkage IV Panel (Illumina) for families 1 and 2. We
assumed an autosomal recessive model. The frequency
of the deleterious allele was set to 0.001, and the pen-
etrance to 99% ( ; ; ;qp 0.001 f p 0.0 f p 0.0 f p1 2 3
). Data analysis revealed a single candidate region,0.99
with a maximum multipoint LOD score of 3.7 at the
tip of chromosome 9 and distal of marker rs3132332
(ﬁg. 2). Linkage was supported by microsatellite marker
analysis in all ﬁve families. The maximum multipoint
LOD score with allowance for heterogeneity was 2.8
distal of marker D9S158. Most of the LOD score came
from families 1 and 2 (ﬁg. 3). Families 4 and 5 were too
small to give prominent LOD scores but were in agree-
ment with linkage to this locus. Family 3 showed LOD
scores of 1 in this region. Ultimately, it was discovered
that the affected individuals in this family were com-
pound heterozygous, although the family was consan-
guineous. Data analysis without the assumption of con-
sanguinity in family 3 resulted in a LOD score of 4.4
distal of marker D9S1826.
Mutation Analysis
The candidate region between marker D9S1826 and
the chromosome end extends across 2.7Mbp. According
to Ensembl release 31.35d, the region contained 85
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Figure 3 Genomewide linkage analysis of families 1 and 2. Analysis was performed using ALLEGRO ( ; ; ;qp 0.001 f p 0.0 f p 0.01 2
) and included affected and unaffected family members. Depicted are summary LOD scores under the assumption of homogeneity.f p 0.993
genes. Among these was an obvious candidate gene,
the sodium-phosphate cotransporter type IIc gene
(SLC34A3). SLC34A3 consists of 13 exons, with the
initiation codon located in exon 2. Sequencing of the
entire exon sequence and the ﬂanking intronic regions
revealed one heterozygous, two compound heterozy-
gous, and two homozygous mutations in the affected
individuals (ﬁg. 1). Furthermore, the parents were shown
to be heterozygous. Three of the mutations are predicted
to result in a transcript with a prematurely terminated
translation product: the proband in family 1 had a ho-
mozygous 1-bp deletion in exon 9 (c.905delC), one mu-
tation in family 4 disrupts an essential residue at the
intron 4 donor splice site (c.3042TrC), and one
mutation in family 5 was a 1-bp deletion in exon 7
(c.744delC). The other mutations were missense muta-
tions and a silent mutation at the last nucleotide position
of exon 8 (c.846GrA), which might lead to an aberrant
splicing product. Attempts to conﬁrm this consequence
in peripheral blood leukocyte mRNA have been unsuc-
cessful because of low abundance of SLC34A3 mRNA
in this tissue. However, the splice-site prediction score
(NNSPLICE version 0.9; see Splice Site Prediction by
Neural Network Web site) decreased from 0.78 to 0.11.
We found only a heterozygous mutation in family 5.
Attempts to ﬁnd a second mutation by searching for
deletions with quantitative PCR failed. All mutations
from the ﬁve families were not found in 350 European
and 93 Israeli-Arabic control individuals.
We then sequenced DNA from another 22 individuals
with hypophosphatemic rickets, for whom mutations in
the PHEX and FGF23 genes had been excluded by se-
quencing and for whomwe had received incomplete clin-
ical reports. We did not ﬁnd homozygous or compound
heterozygous SLC34A3 mutations in these patients.
During sequencing of the families with HHRH and the
additional 22 individuals with hypophosphatemic rick-
ets, we found ﬁve nonsynonymous and four synonymous
sequence variations (table 2). One of the nonsynony-
mous changes (p.D237N) was found in a single control
chromosome; all others were present in at least six con-
trol chromosomes. We concluded that these variants,
with the possible exception of p.D237N, are polymor-
phisms because, under the assumption of random mat-
ing, a disease-allele frequency of 0.014 (6/440) would
result in a recessive-disease frequency of 0.00019, which
is much higher than the incidence of HHRH.
Phylogeny
SLC34A3 has recently been identiﬁed as the third
member of the sodium-phosphate cotransporter family
type II, also called “NaPi-IIc” or “Npt2c.” In rats, it has
been reported to be expressed only in kidney and at high
levels at weaning age (Segawa et al. 2002). The protein
has been shown to be localized at the apical membrane
of proximal tubular cells (Segawa et al. 2002) and to be
reduced in Hyp mice (Tenenhouse et al. 2003), which
suggests that it is involved in renal phosphate reabsorp-
tion. To study whether the missense mutations are evo-
lutionarily conserved, we undertook database searches
and protein predictions from the genomic sequence of
several vertebrate species to construct a phylogenetic tree
of all type II cotransporters (ﬁg. 4). SLC34A3 is present
in eutherians, marsupials, and amphibians, because it
can be found in human, mouse, rat, opossum, and Xen-
opus laevis, whereas it cannot be detected in ﬁsh ge-
nomes (ﬁg. 5). Instead, zebraﬁsh, having the most com-
plete ﬁsh genome sequence, has four NaPi cotransporter
genes, two each belonging to the type IIa family and the
more divergent type IIb family. These four genes seem
to be transcribed, since all sequences are supported by
expressed sequence tags. One of themutated amino acids
(p.A413E) is conserved in all but one of the investigated
cotransporters, one (p.S192L) in all type IIc cotrans-
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Figure 4 Amino acid alignment of SLC34A1, SLC34A2, and
SLC34A3 proteins from different vertebrate species. The legend is
available in its entirety in the online edition of The American Journal
of Human Genetics.
Table 2
SLC34A3 Sequence Variations
VARIATION GROUP
AND SEQUENCE CHANGE PATIENTa
dbSNP
ACCESSION
NUMBER
EXON
OR UTR
CONTROL INDIVIDUALSb
n Genotype 11 Genotype 12 Genotype 22
Mutations:
c.3042TrC 5669 (comp. het.) … Exon 4 353 (93) TT: 353 (93) TC: 0 (0) CC: 0 (0)
c.575CrT (p.S192L) … … Exon 7 350 (93) CC: 350 (93) CT: 0 (0) TT: 0 (0)
c.744delC 5919 (het.) … Exon 7 354 CC: 354 CdelC: 0 delCdelC: 0
c.905delC 23724c (hom.) … Exon 9 352 CC: 352 CdelC: 0 delCdelC: 0
c.1058GrT (p.R353L) 23727c (hom.) … Exon 10 353 (93) GG: 353 (93) GT: 0 (0) TT: 0 (0)
c.1238CrA (p.A413E) 27018c (comp. het.) … Exon 12 338 (91) CC: 338 (91) CA: 0 (0) AA: 0 (0)
c.846GrA (p.P282P) … … Exon 8 338 (91) GG: 338 (91) GA: 0 (0) AA: 0 (0)
Nonsynonymous variations:
c.200GrA (p.R67H) … ss48531127 Exon 4 366 GG: 306 GA: 57 AA: 3
c.539GrC (p.G180A) … ss48531129 Exon 6 337 (92) GG: 330 (88) GC: 7 (4) CC: 0 (0)
c.709GrA (p.D237N) … … Exon 7 334 (92) GG: 334 (91) GA: 0 (1) AA: 0 (0)
c.1009GrA (p.G337S) … ss48531134 Exon 10 338 (93) GG: 331 (86) GA: 7 (7) AA: 0 (0)
c.1538TrA (p.V513E) … ss48531135 Exon 13 353 (93) TT: 265 (83) TA: 85 (10) AA: 3 (0)
Synonymous variations:
c.204CrT (p.R68R) … ss48531128 Exon 4 354 (93) CC: 348 (92) CT: 6 (1) TT: 0 (0)
c.625CrT (p.L209L) … ss48531130 Exon 7 338 (93) CC: 332 (93) CT: 6 (0) TT: 0 (0)
c.757TrC (p.L249L) … ss48531131 Exon 8 353 (93) TT: 124 (30) TC: 176 (44) CC: 53 (18)
c.942GrC (p.A314A) … ss48531133 Exon 10 338 GG: 332 GC: 6 CC: 0
Noncoding variations:
c.109410TrA … ss48531132 Exon 11 351 (92) TT: 282 (55) TA: 67 (33) AA: 2 (4)
c.180014ArC … ss48531136 3′ UTR 338 (92) AA: 104 (39) AC: 171 (44) CC: 63 (9)
a comp. het. p compound heterozygous; het. p heterozygous; hom. p homozygous.
b n p number of control individuals tested for a particular variation. Genotypes are followed by the number of control individuals tested
who have that genotype. The number of Arabic controls is given in parentheses.
c Arabic index patient.
porters, and one (p.R353L) in only human and mouse
type IIc cotransporters.
FGF23 Plasma Levels
FGF23 is a phosphaturic factor (Shimada et al. 2001;
White et al. 2001) that is elevated in most patients with
X-linked hypophosphatemia and in patients with TIO
(Jonsson et al. 2003). It is thought that FGF23 directly
or indirectly inhibits renal phosphate reabsorption
through SLC34A1 and SLC34A3 sodium-phosphate co-
transporters. If this were the case, one would expect
normal or low FGF23 plasma levels in individuals with
HHRH. We measured FGF23 plasma levels with two
ELISAs, detecting C-terminal/intact and only intact
FGF23 in four of the affected individuals and in their
relatives and controls. The C-terminal assays showed
normal levels in the affected persons, whereas the intact
assay revealed low-normal and undetectable FGF23
plasma levels in three of four patients (table 3).
Discussion
We identiﬁed the gene mutated in HHRH by a positional
candidate-gene approach. Several observations substan-
tiate the causal role of SLC34A3 mutations in HHRH.
We identiﬁed two different homozygous, one heterozy-
gous, and two compound heterozygous SLC34A3 mu-
tations in ﬁve families that were not present in 440 con-
trol individuals. At least three of seven mutations are
predicted to result in loss of function of the sodium-
phosphate cotransporter. Final proof of the causal role
of the missense mutations awaits functional studies. We
also found ﬁve nonsynonymous sequence variations. All
but one are considered to be polymorphisms because the
minor-allele frequency was at least 8%. That HHRH is
caused by loss-of-function mutations is compatible with
the HHRH phenotype and the current view of renal
phosphate regulation. Long-term phosphate supplemen-
tation alone results in reversal of the clinical and bio-
chemical abnormalities in HHRH, with the exception of
decreased renal phosphate reabsorption. Thus, it is likely
that HHRH is a primary disorder of renal phosphate
reabsorption.
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Table 3
FGF23 Plasma Levels
Patient
C-Terminal/Intact FGF23a
(RU/ml)
Intact FGF23b
(pg/ml)
23727 28 5
27018 33 ND
5669 53 35
5919 30 9
a Normal !150 reference units (RU)/ml.
b Normal 8–54 pg/ml. ND p not detectable.
Figure 5 Dendrogram of SLC34A1, SLC34A2, and SLC34A3 proteins from different vertebrate species. The sequences were obtained
from GenBank or Ensembl or were predicted by tblastn and Genewise from the corresponding genome sequence and were aligned using ClustalW
(ﬁg. 4).
A key process in phosphate homeostasis is the trans-
port of inorganic phosphate from the primary urine
across the renal proximal tubule, which involves sec-
ondary active sodium-phosphate (NaPi) cotransport at
the apical brush border membrane of the proximal renal
tubular epithelium. The closely related type II NaPi co-
transporter genes, SLC34A1 (Magagnin et al. 1993) and
SLC34A3 (Segawa et al. 2002), are predominantly ex-
pressed in the kidney and are thought to play a key role
in renal phosphate handling. The importance of Slc34a1
in renal handling of Pi was demonstrated in Npt2a
knockout mice (Beck et al. 1998). Mice homozygous for
the disrupted Npt2a gene exhibit increased urinary Pi
excretion, hypophosphatemia, an adaptive increase in
serum 1,25(OH)2D, and hypercalciuria. These biochem-
ical features are typical for patients with HHRH, yet
Npt2a/ mice do not show rickets.
The Slc34a3 protein is maximally upregulated in
Npt2a/ mice and may therefore be also involved in
physiological phosphate reabsorption, although upreg-
ulation is obviously not sufﬁcient to compensate for
the phosphate loss through Slc34a1 (Tenenhouse et al.
2003). It has been estimated that SLC34A1 accounts for
∼70%–80% of NaPi-cotransport activity (Murer et al.
2004). A signiﬁcant part of the remaining activity might
be related to SLC34A3 (Segawa et al. 2002; Tenenhouse
et al. 2003).
Both transporters are likely to be regulated by the
endopeptidase homolog PHEX and the phosphaturic
factor FGF23, since decreased renal Slc34a1 and Slc34a3
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mRNA or protein expression has been reported in
FGF23 transgenic mice and in Hyp mice (Tenenhouse
et al. 1994; Larsson et al. 2004; Shimada et al. 2004),
which harbor a Phex deletion (Strom et al. 1997) and
serve as a model for X-linked hypophosphatemia. It is
further likely that PHEX acts upstream of FGF23, since
double-mutant Phex/Hyp/ and FGF23/ mice do
not rescue the FGF23/ phenotype (Sitara et al. 2004),
although there is evidence against a direct interaction
between PHEX and FGF23 (Liu et al. 2003; Benet-Pages
et al. 2004). Hypophosphatemia caused by both PHEX
and FGF23 mutations affects not only renal phosphate
reabsorption but also the synthesis of 1,25(OH)2D due
to the lack of upregulation of 25-hydroxyvitamin D 1a-
hydroxylase (Scriver et al. 1978; Lobaugh and Drezner
1983). This upregulation in response to low serum phos-
phate is intact in HHRH, which further argues for a
primary defect in renal phosphate reabsorption in this
condition.
Heterozygous mutations in the SCL34A1 gene have
been described in two individuals with nephrolithiasis,
renal phosphate loss, and hypophosphatemia (Prie´ et
al. 2002), but that report has not been conﬁrmed yet.
Hypophosphatemia has also been described in hetero-
zygous Npt2a/ mice, although they do not develop
nephrolithiasis (Beck et al. 1998). Of note, borderline
hypercalciuria and hypophosphatemia have been de-
scribed in individuals presumably carrying a heterozy-
gous SLC34A3 mutation (Tieder et al. 1987). Hyper-
calciuria is also documented in heterozygous mutation
carriers in the present study and may predispose these
individuals to nephrolithiasis and skeletal abnormalities.
In summary, the identiﬁcation of SLC34A3 mutations
in HHRH adds the protein SLC34A3 to the group of
proteins—PHEX, FGF23, SLC34A1, and GALNT3—
that are all involved in renal phosphate reabsorption.
The interaction and regulation of these proteins remain
largely elusive. The identiﬁcation of mutated genes in
additional, rare forms of hypophosphatemia may help
to unravel these questions.
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Appendix A
Table A1
Primers for the Ampliﬁcation of SLC34A3 Exons
EXON(S)
PRIMER SEQUENCE
(5′r3′)
ANNEALING
TEMPERATURE
(C)
LENGTH
(bp)Forward Reverse
1 TCTTTGACCTGCAACTGCTC CACCTGGACCCCTCCAC 60 265
2 and 3 TGTGAATCCAGCTTGTGAGG CTGTCTCCCCAGTCCCG 60 637
4 and 5 AGAGAATGAGGGGCCTGG GACACCCGGACAGTCAGC 60 523
6 and 7 CAGCATGGTGGCTGCTAAG CAGACCCTCCGCTGACC 60 595
8 and 9 CCCGGGTGAGTCCTGAG GGCTGTGCTGTTCCTCTCC 60 448
10 and 11 GACAGGCTGCCCTGTGAG CACCACAGGACCCCAGC 60 560
12 GACAGAGGCCTCGGGAAC CTGTCTGTGGGGCTGAGAG 60 247
13 GTAGGGTGGAGGAGGGCAG GTGTCCACCAGGAGGCAG 60 768
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
Ensembl, http://www.ensembl.org/ (for proteins from chicken [acces-
sion numbers ENSGALP00000004850 and BU122185], Xeno-
pus [accession numbers ENSXETP00000050672 and CX972852],
zebraﬁsh [accession numbers ENSDARP017391, C0920054,
ENSDARP00000041987, and CR929642], and Fugu [accession
numbers SINFRUP00000132898 and SINFRUP00000149494])
ExonPrimer, http://ihg.gsf.de/ihg/ExonPrimer.html
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for sequences
from human [accession numbers NP_003043.2, NP_006415.1,
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